Association of lower DLL3 methylation and increased expression with sensitivity to Bcl-2 inhibitors suggest that the use of the Bcl-2 inhibitors in the ASCL1-high SCLC lineage may be considered. Here, ASCL1 is linked to small cell lung carcinoma.